Gilead Sciences, Inc. To Appeal FDA Cystic Fibrosis Trial Demand
LOS ANGELES, Nov 13 (Reuters) - Gilead Sciences Inc (GILD.O: Quote, Profile, Research, Stock Buzz) plans to appeal a request by the U.S. Food and Drug Administration for an additional clinical study of the company's experimental cystic fibrosis drug, a spokeswoman said on Thursday.